ArticleScientific reports2023
Enhancing radiative efficiency in MHD micropumps using plasma-infused hybrid bioconvective nanofluids for advanced radiative oncology at tertiary level.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research paper investigates the optimization of radiation performance of a plasma-based bioconvective nanofluid integrated Magneto-hydrodynamic (MHD) micropump for radiative oncology. It addresses a literature gap by analysing the radiative impact of blood-based hybrid nanofluids in MHD micropumps. Three blood-based bio-convective radiating hybrid nanofluids-blood-Pt, blood-Au and blood-MWCNT are studied to understand their radiation behaviour in MHD pump while being employed as transportation medium. The investigation employs two non-dimensional parameters, namely Rd (Radiation number) and Ha (Hartmann number), to examine the fluid dynamics, magnetic characteristics, and electrical properties of the MHD micropump. The temperature gradient, velocity distribution, and pressure drop along the flow channel are examined within the specified range of Rd and Ha. Magnetic flux density (MFD) and electric flux intensity (EFI) are evaluated to understand nanoparticle behaviour during drug delivery and blood transportation. Findings highlight that MWCNT and Pt are the most efficient bioconvective nanoparticles for plasma transportation under high radiative conditions. MWCNT-based blood flow exhibits desirable characteristics, including sufficient intake pressure of 4.5 kPa and minimal relative pressure drop of 34%. Coherence between radiation flux and electromagnetic flux reduces pumping power and ensures uniform heat dissipation for improved drug delivery. Au nanoparticles provide moderate magnetic flux density with least fluctuation within the range of Ha and Rd number (2.57 T to 4.39 T), even in highly radiative environments (such as-Rd = 4, Rd = 5), making them suitable for applications like embedded chemotherapy or cell treatment. Au nanoparticles maintain moderate electrical flux intensity with a minimal drop of 16nA, particularly at higher radiative environments influenced by the Radiation number (Rd = 4 to Rd = 5) while Ha values from Ha = 2 to Ha = 4. Conclusively, it has been identified that MWCNT and Au are superior nanofluids for advanced radiative oncological treatments. These nanofluids have the potential to enhance plasma transportation, thermal regulation, and aetilogical disease management. The present study provides significant findings on enhancing the radiation performance in MHD micropumps through utilization of blood-based hybrid nanofluids, thereby offering potential advantages to the domain of biomedical engineering.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.